TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01698567

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antithrombin III
Description: ATIII will be dosed using the formula recommended by the manufacturer:~(goal activity - baseline activity) x weight (kg) x .714 (Assume: start with 35% activity \[7\], goal 120% activity\[18\], so dose = 120-35 x wt (kg) x .714, e.g. 5 kg infant: 85 x 5 x .714 = 303 units)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo (normal saline) after induction of anesthesia and before commencement of bypass. ATIII will be dosed using the formula recommended by the manufacturer: (goal activity - baseline activity) x weight (kg) x .714 (Assume: start with 35% activity \[7\], goal 120% activity\[18\], so dose = 120-35 x wt (kg) x .714, e.g. 5 kg infant: 85 x 5 x .714 = 303 units)
Study: NCT01801787

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: active vs. sham tDCS left hemisphere
Study: NCT00908960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Study: NCT03509038

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exploratory pathophysiology Study
Description: Urodynamic tests before and after bariatric surgery in obese incontinent women before and after bariatric surgery
Study: NCT01342718

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Herbal extract granule and probiotics
Description: The herbal extract granule, Gwakhyangjeonggisan granule, consists of 11 herbs. Ingredients: Agastachis, Perillae Folium, Angelicae Radix, Arecae Pericarpium, Hoelen, Magnoliae officinalis Cortex, Atractylis Rhizoma, Aurantii nobilis Percarpium, Pinelliae Rhizoma, Platycodi Radix, Glychrrhizae Radix. Dosage and frequency: 1 pack (3g), 3 packs per day (2 hours after morning, afternoon and evening meal)~The probiotics, Duolac7S, consist of 7 bacteria. Ingredients: Lactobacillus acidophilus, L. plantarum, L. rhamnosus, Bifidobacterium breve, B. lactis, B. longum, Streptococcus thermophilus. Dosage and frequency: 1 capsule (5✕1,000,000,000 bacteria/capsule \[7✕100,000,000 viable cells/strain\]), 2 capsules per day (2 hours after morning and evening meal)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Herbal extract granule and placebo probiotics
Description: The herbal extract granule, Gwakhyangjeonggisan granule, consists of 11 herbs. Ingredients: Agastachis, Perillae Folium, Angelicae Radix, Arecae Pericarpium, Hoelen, Magnoliae officinalis Cortex, Atractylis Rhizoma, Aurantii nobilis Percarpium, Pinelliae Rhizoma, Platycodi Radix, Glychrrhizae Radix. Dosage and frequency: 1 pack (3g), 3 packs per day (2 hours after morning, afternoon and evening meal).~Duolac7S placebo has the same form, color and flavor as experimental intervention (Duolac7S). The dosage, frequency and duration is also the same as experimental intervention (Duolac7S).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo herbal extract granule and probiotics
Description: The Gwakhyangjeonggisan placebo has the same form, color and flavor as experimental intervention (Gwakhyangjeonggisan). The dosage, frequency and duration is also the same as experimental intervention (Gwakhyangjeonggisan).~The probiotics, Duolac7S, consist of 7 bacteria. Ingredients: Lactobacillus acidophilus, L. plantarum, L. rhamnosus, Bifidobacterium breve, B. lactis, B. longum, Streptococcus thermophilus. Dosage and frequency: 1 capsule (5✕1,000,000,000 bacteria/capsule \[7✕100,000,000 viable cells/strain\]), 2 capsules per day (2 hours after morning and evening meal)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo herbal extract granule and placebo probiotics
Description: The Gwakhyangjeonggisan placebo has the same form, color and flavor as experimental intervention (Gwakhyangjeonggisan). The dosage, frequency and duration is also the same as experimental intervention (Gwakhyangjeonggisan).~Duolac7S placebo has the same form, color and flavor as experimental intervention (Duolac7S). The dosage, frequency and duration is also the same as experimental intervention (Duolac7S).
Study: NCT02992496

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: 1mg/kg, 6 applications over 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam Hydrochloride
Description: 0.03mg/kg, 6 applications over 2 weeks
Study: NCT03243838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: All enrolled patients were administered oral apatinib at a dose of 250 mg once daily and intravenously docetaxel (100 mg/m2) every three weeks for four cycles, followed by epirubicin (90 mg/m2) plus cyclophosphamide (600 mg/m2) every three weeks for four cycles. All the treatments were continued until disease progression, patient withdrawal, or unacceptable toxic effects.
Study: NCT00857571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 750 mg Tablet
Description: Single oral dose of 750 mg of PF-02413873 tablets
Study: NCT03916718

Intervention type: BEHAVIORAL
Intervention: Care EcoSystem
Description: This is a care management program and health care outcomes feasibility study utilizing the dementia Care Ecosystem (CE) program developed at UCSF and tailored to high need Ochsner PWD (patient with dementia) and their CGs (caregivers). Dyads (CGs and PWD) will receive a tailored clinical assessment addressing dementia severity, PWD and CG needs, education/strategies to management common dementia issues, medical issues and medication reconciliation, caregiver wellness strategies, linkages to community-based resources, advance care planning, education about the risk of ED and hospitalization, and care coordination with other specialties. Dyads will be followed on a monthly basis to monitor needs, provide support, and problem solve issues.
Study: NCT01837628

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paraffin Oil
Study: NCT02861950

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caudal block with ropivacaine
Description: Patients in this arm will receive a caudal block with ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: penile nerve block with bupivacaine
Description: Patients in this arm will receive a penile block with bupivacaine
Study: NCT02815748

Intervention type: DRUG
Group type: OTHER
Intervention: SP2086
Description: SP2086 was taken only one time at 100mg dose in health volunteers
Study: NCT01262872

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK 2189242A (LD formulation 1)
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK 2189242A (HD formulation 2)
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK 2189242A (HD formulation 2)
Description: Intramuscular injection
Study: NCT04443556

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Before the closure of the thoracotomy, the surgeon will place two catheters through a Tuohy needle into fascial planes for continue the RISS block. First catheter tip will be placed towards the interfascial planes between the rhomboid major and intercostal muscles and the second catheter tip will be placed in subserratus fascial plane. Continue local anesthetics will be injected through the catheters for 48 hours. Also an IV patient-controlled analgesia device containing tramadol will be provided. Tramadol consumptions and postoperative numeric rating scale (NRS) scores for pain will be recorded.

Intervention type: OTHER
Group type: OTHER
Intervention: IV PCA
Description: An IV patient-controlled analgesia device containing tramadol will be provided. Tramadol consumptions and postoperative numeric rating scale (NRS) scores for pain will be recorded.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IV PCA
Description: An IV patient-controlled analgesia device containing tramadol will be provided. Tramadol consumptions and postoperative numeric rating scale (NRS) scores for pain will be recorded.
Study: NCT03650972

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Samarin
Description: Arm: Active Comparator: B, Bicarbonate group When labour arrest is diagnosed and the first AFL \> 12 mmol/L the participants will be randomized to two groups. In group B the participant will drink bicarbonate (2 packages of Samarin®) dissolved in 200 ml of water. Then after one hour the AFL will be measured again and the stimulation with oxytocin will be started if there is no progress in the cervix.
Study: NCT03168464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab (3mg/kg) is given concurrently (+/- 24hrs from first RT dose) with radiation therapy on Day 1 of the study. On day 22 the combined treatment of ipilimumab plus nivolumab will start (nivolumab 240mg q 2 weeks, ipilimumab 1mg/kg q 6 weeks), and administered until evidence of progression.
Study: NCT00804765

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic education
Description: Intensive training individual and collective teaching

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Follow-up
Description: classical follow-up with two individual consultations
Study: NCT03168464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: On day 22 the combined treatment of ipilimumab plus nivolumab will start (nivolumab 240mg q 2 weeks, ipilimumab 1mg/kg q 6 weeks), and administered until evidence of progression.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Ipilimumab (3mg/kg) is given concurrently (+/- 24hrs from first RT dose) with radiation therapy on Day 1 of the study.
Study: NCT00951431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Esomeprazole 20mg daily for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in the form of study drug
Study: NCT03172936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIW815
Description: MIW 815 (ADU-S100) is a STING agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIW815
Description: MIW 815 (ADU-S100) is a STING agonist
Study: NCT01262872

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK 2189242A (HD formulation 2)
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Synflorix™
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Synflorix™
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar13™
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar13™
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix™-HepB/Hib
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix™-HepB/Hib
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix™-HepB/Hib
Description: Intramuscular injection
Study: NCT01815294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOXIL/CAELYX (doxorubicin) Treatment Sequence AB
Description: Cycle 1 = Treatment A, Cycle 2 = Treatment B
Study: NCT01262872

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tritanrix™-HepB/Hib
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tritanrix™-HepB/Hib
Description: Intramuscular injection
Study: NCT01815294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOXIL/CAELYX (doxorubicin) Treatment Sequence AB
Description: Cycle 1 = Treatment A, Cycle 2 = Treatment B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOXIL/CAELYX (doxorubicin) Treatment Sequence BA
Description: Cycle 1 = Treatment B, Cycle 2 = Treatment A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOXIL/CAELYX (doxorubicin) Treatment Sequence BA
Description: Cycle 1 = Treatment B, Cycle 2 = Treatment A
Study: NCT01262872

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tritanrix™-HepB/Hib
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polio Sabin™
Description: Orally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polio Sabin™
Description: Orally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polio Sabin™
Description: Orally
Study: NCT03462771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fish oil
Description: 4g of fish oil daily for 14 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sunflower oil
Description: 4g of sunflower oil daily for 14 weeks
Study: NCT03172936

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PDR001
Description: PDR001 is an anti-PD-1 antibody
Study: NCT04421534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactoferrin
Description: adding lactoferrin to standard of care treatment regimens

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactoferrin
Description: adding lactoferrin to standard of care treatment regimens

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactoferrin
Description: adding lactoferrin to standard of care treatment regimens
Study: NCT06102278

Intervention type: OTHER
Intervention: Peritoneal Metastasis
Description: Patients experiencing postoperative peritoneal metastasis

Intervention type: OTHER
Intervention: Peritoneal Metastasis
Description: Patients experiencing postoperative peritoneal metastasis
Study: NCT02489799

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Advance care planning video
Description: This is a video involving interviews with patients, a family member, two surgeons, an anesthesiologist, and an ICU nurse; these interviewees describe the typical events during a hospitalization for a major surgery and encourage the viewer to do some planning before surgery - the planning includes: (i) naming a person to make decisions for the participant, (ii) having a conversation with that person about goals and values, and (iii) continuing that conversation with the participant's surgeon.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control video
Description: This is a video showing the history of The Johns Hopkins Hospital and emphasizing that The Johns Hopkins Hospital is a great place to receive medical care.
Study: NCT00589745

Intervention type: OTHER
Group type: OTHER
Intervention: Nasal potential difference measurement
Description: Nasal potential difference measurement involves dripping small amounts of 5 test solutions into the anterior nostril. This is designed to test the ability of the cells to regulate the movement of salt and water in people with features of CF in whom the diagnosis is not entirely clear.
Study: NCT02450786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil is started in patients with Parkinson's disease mild cognitive impairment with 5mg for 8 weeks followed by dose up to 10mg and then maintained for 40 weeks. Participants who are not tolerable to dose of 10mg due to any issues of adverse effects would be maintained with donepezil 5mg exclusively in remained period.
Study: NCT02988232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sogyeonghwalhyeol-tang
Description: herbal extract

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: extract powder with same appearance, odor and color as SGHH
Study: NCT01018992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK561679
Description: GSK561679, oral administration, 350mg/day, 6 week administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo, oral administration, 1 pill/day for 6 weeks
Study: NCT02400749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Apremilast tablets will be provided to sites in blister cards.~Patients will be provided a titration blister pack containing apremilast 10 mg, 20 mg and 30 mg at the Day 0 and week 16 visits (refer to section 6.1). Following the 6 day titration period (for Day 0 and week 16) blister packs will contain apremilast 30 mg bid or placebo bid.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Apremilast
Description: Apremilast tablets will be provided to sites in blister cards.~Patients will be provided a titration blister pack containing apremilast 10 mg, 20 mg and 30 mg at the Day 0 and week 16 visits (refer to section 6.1). Following the 6 day titration period (for Day 0 and week 16) blister packs will contain apremilast 30 mg bid or placebo bid.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets will be provided to sites in blister cards.
Study: NCT02660086

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized nutrition feedback
Description: Automated personalized nutrition feedback about cafeteria food purchases (weekly); social norms and small financial incentives to promote healthy purchases (monthly)
Study: NCT03647800

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: APVO436
Description: APVO436

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: APVO436
Description: APVO436
Study: NCT02499991

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: memory
Description: keep track of social events in diary for memory recall. Used by treatment group
Study: NCT00785798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: 200mg to 400 mg twice daily on days 1-7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin (PLD), Doxil
Description: IV 30mg/m2 on day 3 of a 21-day cycle
Study: NCT00051740

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Adaptation Therapy (CAT)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Minimal Environmental Supports (MES)
Study: NCT01946256

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Erythromycin
Study: NCT04254965

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: Treatment including instrument playing, singing, lyrics modification/music organized play, listening to music and discussing each treatment process.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music therapy
Description: Treatment including instrument playing, singing, lyrics modification/music organized play, listening to music and discussing each treatment process.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biosignal analysis
Description: Measurement of facial expression emotion recognition, electrodermal activity, heart rate variability, sleep pattern, blood pressure, and electromyogram.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biosignal analysis
Description: Measurement of facial expression emotion recognition, electrodermal activity, heart rate variability, sleep pattern, blood pressure, and electromyogram.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Biosignal analysis
Description: Measurement of facial expression emotion recognition, electrodermal activity, heart rate variability, sleep pattern, blood pressure, and electromyogram.
Study: NCT01092689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PhiP
Description: 1 capsule of 84 micrograms; 15.6 micro-curies \[14C\]PhIP
Study: NCT01262872

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Polio Sabin™
Description: Orally

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Polio Sabin™
Description: Orally

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Polio Sabin™
Description: Orally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M-Vac™
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M-Vac™
Description: Intramuscular injection
Study: NCT03782545

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cutera truSculpt Device
Description: The Cutera truSculpt Device uses radio frequency (RF) energy to provide topical heating for the purpose of elevating tissue temperature for the treatment of selected medical conditions, such as temporary reduction in the appearance of cellulite.
Study: NCT00560209

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ONO-1101
Description: placebo for 1 minute IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-1101
Description: 0.06 mg/kg for 1 minute IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-1101
Description: 0.125 mg/kg for 1 minute IV
Study: NCT00587171

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patching
Description: 2 hours daily patching

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Patching
Description: 2 hours daily patching

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Near activities
Description: 30 minutes daily near activities at home

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Near activities
Description: 30 minutes daily near activities at home

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active vision therapy
Description: 30 minutes of daily at-home active vision therapy and a weekly 45 minute in-office active vision therapy session

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control vision therapy
Description: 30 minutes of daily at-home control vision therapy and a weekly 45 minute in-office control vision therapy session
Study: NCT02857686

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intravenous regional anaesthesia
Description: tourniquet over the arm and intravenous lidocaine with a dose of 4 mg/kg
Study: NCT01262872

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M-Vac™
Description: Intramuscular injection
Study: NCT02888899

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stool bulking agent (sterculia or ispaghula husk)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stool bulking agent (sterculia or ispaghula husk)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PTNS
Study: NCT01578928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOM230